메뉴 건너뛰기




Volumn 15, Issue 23, 2014, Pages 10045-10051

Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Neurokinin 1 receptor antagonist; Substance P

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; DEXAMETHASONE; MORPHOLINE DERIVATIVE; SEROTONIN 3 AGONIST;

EID: 84921825722     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10045     Document Type: Short Survey
Times cited : (7)

References (36)
  • 1
    • 84869416865 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study
    • Albany C, Brames MJ, Fausel C, et al (2012). Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol, 30, 3998-4003.
    • (2012) J Clin Oncol , vol.30 , pp. 3998-4003
    • Albany, C.1    Brames, M.J.2    Fausel, C.3
  • 2
    • 0038047690 scopus 로고    scopus 로고
    • Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
    • Blum RA, Majumdar A, McCrea J, et al (2003). Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther, 25, 1407-19.
    • (2003) Clin Ther , vol.25 , pp. 1407-1419
    • Blum, R.A.1    Majumdar, A.2    McCrea, J.3
  • 3
    • 79952860744 scopus 로고    scopus 로고
    • Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    • Bergstrom M, Hargreaves RJ, Burns HD, et al (2011). Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci, 1222, 40-8.
    • (2011) Ann N Y Acad Sci , vol.1222 , pp. 40-48
    • Bergstrom, M.1    Hargreaves, R.J.2    Burns, H.D.3
  • 4
    • 0035868769 scopus 로고    scopus 로고
    • Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
    • Campos D, Pereira JR, Reinhardt RR, et al (2001). Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19, 1759-67.
    • (2001) J Clin Oncol , vol.19 , pp. 1759-1767
    • Campos, D.1    Pereira, J.R.2    Reinhardt, R.R.3
  • 5
    • 0035053631 scopus 로고    scopus 로고
    • Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
    • Cocquyt V, Van Belle S, Reinhardt RR, et al (2001). Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer, 37, 835-42.
    • (2001) Eur J Cancer , vol.37 , pp. 835-842
    • Cocquyt, V.1    Van Belle, S.2    Reinhardt, R.R.3
  • 6
    • 0037403701 scopus 로고    scopus 로고
    • Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
    • Chawla SP, Grunberg SM, Gralla RJ, et al (2003). Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer, 97, 2290-300.
    • (2003) Cancer , vol.97 , pp. 2290-2300
    • Chawla, S.P.1    Grunberg, S.M.2    Gralla, R.J.3
  • 7
    • 84897515769 scopus 로고    scopus 로고
    • Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin
    • Choi CH, Kim MK, Park JY, et al (2014). Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer, 22, 1181-7.
    • (2014) Support Care Cancer , vol.22 , pp. 1181-1187
    • Choi, C.H.1    Kim, M.K.2    Park, J.Y.3
  • 8
    • 1642513757 scopus 로고    scopus 로고
    • The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials
    • de Wit R, Herrstedt J, Rapoport B, et al (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer, 40, 403-10.
    • (2004) Eur J Cancer , vol.40 , pp. 403-410
    • de Wit, R.1    Herrstedt, J.2    Rapoport, B.3
  • 9
    • 84872584635 scopus 로고    scopus 로고
    • Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
    • Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013). Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J, 43, 73-6.
    • (2013) Intern Med J , vol.43 , pp. 73-76
    • Gao, H.F.1    Liang, Y.2    Zhou, N.N.3    Zhang, D.S.4    Wu, H.Y.5
  • 10
    • 0347816226 scopus 로고    scopus 로고
    • Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group
    • Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.
    • (2003) J Clin Oncol , vol.21 , pp. 4112-4119
    • Hesketh, P.J.1    Grunberg, S.M.2    Gralla, R.J.3
  • 11
    • 2342483811 scopus 로고    scopus 로고
    • Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
    • Hargreaves R, Ferreira JC, Hughes D, et al (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry, 55, 1007-12.
    • (2004) Biol Psychiatry , vol.55 , pp. 1007-1012
    • Hargreaves, R.1    Ferreira, J.C.2    Hughes, D.3
  • 12
    • 33646412299 scopus 로고    scopus 로고
    • Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    • Hesketh PJ, Grunberg SM, Herrstedt J, et al (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer, 14, 354-60.
    • (2006) Support Care Cancer , vol.14 , pp. 354-360
    • Hesketh, P.J.1    Grunberg, S.M.2    Herrstedt, J.3
  • 13
    • 79956158979 scopus 로고    scopus 로고
    • Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race
    • Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
    • (2010) Asian Pac J Cancer Prev , vol.11 , pp. 1523-1527
    • Hassan, B.A.1    Yusoff, Z.B.2
  • 14
    • 77956458957 scopus 로고    scopus 로고
    • Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
    • Hesketh PJ, Aapro M, Street JC, Carides AD (2010). Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer, 18, 1171-7.
    • (2010) Support Care Cancer , vol.18 , pp. 1171-1177
    • Hesketh, P.J.1    Aapro, M.2    Street, J.C.3    Carides, A.D.4
  • 15
    • 84895878181 scopus 로고    scopus 로고
    • Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
    • Hu Z, Cheng Y, Zhang H, et al (2014). Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer, 22, 979-87.
    • (2014) Support Care Cancer , vol.22 , pp. 979-987
    • Hu, Z.1    Cheng, Y.2    Zhang, H.3
  • 16
    • 64449083250 scopus 로고    scopus 로고
    • Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
    • Jordan K, Kinitz I, Voigt W, et al (2009). Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer, 45, 1184-7.
    • (2009) Eur J Cancer , vol.45 , pp. 1184-1187
    • Jordan, K.1    Kinitz, I.2    Voigt, W.3
  • 17
    • 84875152856 scopus 로고    scopus 로고
    • Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
    • Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.
    • (2013) Expert Opin Pharmacother , vol.14 , pp. 757-766
    • Janelsins, M.C.1    Tejani, M.A.2    Kamen, C.3
  • 18
    • 84893430104 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia
    • Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.
    • (2013) Asian Pac J Cancer Prev , vol.14 , pp. 7701-7706
    • Keat, C.H.1    Ghani, N.A.2
  • 19
    • 33845900962 scopus 로고    scopus 로고
    • Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
    • Loos WJ, de Wit R, Freedman SJ, et al (2007). Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol, 59, 407-12.
    • (2007) Cancer Chemother Pharmacol , vol.59 , pp. 407-412
    • Loos, W.J.1    de Wit, R.2    Freedman, S.J.3
  • 20
    • 0037757975 scopus 로고    scopus 로고
    • Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
    • McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24.
    • (2003) Clin Pharmacol Ther , vol.74 , pp. 17-24
    • McCrea, J.B.1    Majumdar, A.K.2    Goldberg, M.R.3
  • 21
    • 0033590464 scopus 로고    scopus 로고
    • Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group
    • Navari RM, Reinhardt RR, Gralla RJ, et al (1999). Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med, 340, 190-5.
    • (1999) N Engl J Med , vol.340 , pp. 190-195
    • Navari, R.M.1    Reinhardt, R.R.2    Gralla, R.J.3
  • 22
    • 53149119534 scopus 로고    scopus 로고
    • Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
    • Nakade S, Ohno T, Kitagawa J, et al (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol, 63, 75-83.
    • (2008) Cancer Chemother Pharmacol , vol.63 , pp. 75-83
    • Nakade, S.1    Ohno, T.2    Kitagawa, J.3
  • 23
    • 82855171513 scopus 로고    scopus 로고
    • Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial
    • Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95.
    • (2011) J Support Oncol , vol.9 , pp. 188-195
    • Navari, R.M.1    Gray, S.E.2    Kerr, A.C.3
  • 24
    • 84921773808 scopus 로고    scopus 로고
    • NCCN clinical Practice guidelines in oncology-antiemesis version I. 2014 (2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
    • (2014)
  • 25
    • 84879161805 scopus 로고    scopus 로고
    • Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
    • Olver IN, Grimison P, Chatfield M, et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer, 21, 1561-8.
    • (2013) Support Care Cancer , vol.21 , pp. 1561-1568
    • Olver, I.N.1    Grimison, P.2    Chatfield, M.3
  • 26
    • 0038728753 scopus 로고    scopus 로고
    • Aprepitant protocol 054 study group.cancer. addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. results from a randomized, double-blind, placebo-controlled trial in Latin America
    • Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Aprepitant protocol 054 study group.cancer. addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8.
    • (2003) Cancer , vol.97 , pp. 3090-3098
    • Poli-Bigelli, S.1    Rodrigues-Pereira, J.2    Carides, A.D.3
  • 27
    • 77952480785 scopus 로고    scopus 로고
    • Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
    • Rapoport BL, Jordan K, Boice JA, et al (2010). Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer, 18, 423-31.
    • (2010) Support Care Cancer , vol.18 , pp. 423-431
    • Rapoport, B.L.1    Jordan, K.2    Boice, J.A.3
  • 28
    • 70649090118 scopus 로고    scopus 로고
    • Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function
    • Rojas C, Thomas AG, Alt J, et al (2012). Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626, 193-9.
    • (2012) Eur J Pharmacol , vol.626 , pp. 193-199
    • Rojas, C.1    Thomas, A.G.2    Alt, J.3
  • 29
    • 84892868999 scopus 로고    scopus 로고
    • Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis
    • Rojas C, Raje M, Tsukamoto T, Slusher BS (2014). Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol, 722, 26-37.
    • (2014) Eur J Pharmacol , vol.722 , pp. 26-37
    • Rojas, C.1    Raje, M.2    Tsukamoto, T.3    Slusher, B.S.4
  • 31
    • 77958559550 scopus 로고    scopus 로고
    • Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
    • Takahashi T, Hoshi E, Takagi M, et al (2010). Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci, 101, 2455-61.
    • (2010) Cancer Sci , vol.101 , pp. 2455-2461
    • Takahashi, T.1    Hoshi, E.2    Takagi, M.3
  • 32
    • 79959331489 scopus 로고    scopus 로고
    • Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients
    • Takahashi T, Nakamura Y, Tsuya A, et al (2011). Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol, 68, 653-9.
    • (2011) Cancer Chemother Pharmacol , vol.68 , pp. 653-659
    • Takahashi, T.1    Nakamura, Y.2    Tsuya, A.3
  • 33
    • 84873695492 scopus 로고    scopus 로고
    • Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy
    • Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90.
    • (2012) Asian Pac J Cancer Prev , vol.13 , pp. 4187-4190
    • Uchino, J.1    Hirano, R.2    Tashiro, N.3
  • 34
    • 0036604223 scopus 로고    scopus 로고
    • Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869
    • Van Belle S, Lichinitser MR, Navari RM, et al (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869. Cancer, 94, 3032-41.
    • (2002) Cancer , vol.94 , pp. 3032-3041
    • Van Belle, S.1    Lichinitser, M.R.2    Navari, R.M.3
  • 35
    • 21044434743 scopus 로고    scopus 로고
    • Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    • Warr DG, Hesketh PJ, Gralla RJ, et al (2005). Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol, 23, 2822-30.
    • (2005) J Clin Oncol , vol.23 , pp. 2822-2830
    • Warr, D.G.1    Hesketh, P.J.2    Gralla, R.J.3
  • 36
    • 58549114412 scopus 로고    scopus 로고
    • A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    • Yeo W, Mo FK, Suen JJ, et al (2009). A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat, 113, 529-35.
    • (2009) Breast Cancer Res Treat , vol.113 , pp. 529-535
    • Yeo, W.1    Mo, F.K.2    Suen, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.